| Abstract [eng] |
Glioblastoma is one of the most aggressive and prevalent primary malignant brain tumors. Despite advancements in treatment, patient survival remains limited, making the pursuit of quality of life a critical concern. Cognitive functioning plays a key role in determining a patient's ability to maintain independence, make decisions, sustain meaningful social relationships, and adapt to the progression of the disease. However, in Lithuania, there is a lack of comprehensive studies examining glioblastoma-induced cognitive function changes and their relationship with disease progression and treatment. The aim of this study is to assess the cognitive function dynamics of a glioblastoma patient during treatment and their association with subjectively perceived quality of life. The research objectives include an analysis of scientific literature on glioblastoma, evaluation of cognitive function and its changes throughout treatment, investigation of the relationship between cognitive impairment and quality of life, and the development of recommendations for patients and their caregivers. A long-term observational study was conducted, integrating both objective and subjective assessment methods. The Montreal Cognitive Assessment (MoCA) and Quality of Life Questionnaires were employed to evaluate cognitive function changes, while semi-structured interviews with the patient’s primary caregiver provided additional insights into cognitive function alterations and their impact on daily life. Longitudinal observations revealed that the cognitive functions of the glioblastoma patient fluctuated dynamically throughout treatment. A significant but temporary decline in cognitive abilities, particularly in abstraction and visuospatial skills, was recorded after surgical intervention and chemoradiotherapy. During temozolomide treatment, cognitive function showed temporary improvement, although fatigue and other symptoms gradually intensified. Approximately 12–13 months post-diagnosis, tumor recurrence led to a pronounced cognitive decline, especially in long-term memory and abstraction abilities. Subjective assessments of physical, emotional, and cognitive functioning also deteriorated over time. Additionally, the patient’s caregiver observed specific cognitive impairments that were not captured through objective testing. These findings highlight the strong link between cognitive changes, treatment phases, and disease progression. Continuous monitoring using a combination of assessment methods is essential for accurately detecting cognitive alterations and ensuring individualized, comprehensive support to maintain the patient's quality of life. |
